This company listing is no longer active

NasdaqGS:EPZM 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 22	53	-208	113	123
31 Mar 22	38	-236	125	123
31 Dec 21	37	-251	134	123
30 Sep 21	34	-267	137	102
30 Jun 21	33	-257	136	102
31 Mar 21	22	-251	133	102
31 Dec 20	16	-232	125	102
30 Sep 20	12	-222	114	0
30 Jun 20	14	-202	100	0
31 Mar 20	17	-192	83	0
31 Dec 19	24	-173	68	126
30 Sep 19	29	-140	57	0
30 Jun 19	23	-141	51	0
31 Mar 19	30	-122	47	0
31 Dec 18	22	-124	44	0
30 Sep 18	12	-137	40	0
30 Jun 18	12	-137	38	0
31 Mar 18	10	-136	38	0
31 Dec 17	10	-134	37	0
30 Sep 17	10	-133	36	0
30 Jun 17	17	-120	35	0
31 Mar 17	8	-120	31	0
31 Dec 16	8	-110	28	0
30 Sep 16	8	-97	27	0
30 Jun 16	2	-96	26	0
31 Mar 16	2	-94	25	0
31 Dec 15	3	-132	24	0
30 Sep 15	12	-125	23	0

양질의 수익: EPZM is currently unprofitable.

이익 마진 증가: EPZM is currently unprofitable.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: EPZM is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.

성장 가속화: Unable to compare EPZM's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: EPZM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (24.5%).

자기자본 수익률

높은 ROE: EPZM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

This company listing is no longer active

Epizyme 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Recent updates

Ipsen Biopharmaceuticals, Inc. completed the acquisition of Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others.

Epizyme, Inc.(NasdaqGS:EPZM) dropped from S&P Global BMI Index

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Epizyme GAAP EPS of -$0.21, revenue of $27.5M

Epizyme Acquisition By Ipsen: CVR Value

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Epizyme, Inc. (NasdaqGS:EPZM) from RP Management LLC and others for approximately $250 million.

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

Epizyme Receives Non-Compliance Letter from Nasdaq

Epizyme Receives Non-Compliance Letter from Nasdaq

Consensus revenue estimates fall by 12%

Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$6.60

Shefali Agarwal Resigns from Epizyme, Inc., Effective April 6, 2022

Epizyme, Inc., Annual General Meeting, May 17, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Epizyme, Inc. has completed a Follow-on Equity Offering in the amount of $85.000001 million.

Price target decreased to US$9.02

Price target decreased to US$9.20

Epizyme, Inc. Provides Revenue Guidance for the Fourth Quarter and Year Ended December 31, 2021

Price target increased to US$12.25

Consensus revenue estimates increase by 19%

Epizyme, Inc. Presents Updates from SYMPHONY-1 Tazemetostat + R² Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2021 ASH Annual Meeting

Epizyme, Inc. Presents Preclinical Data and Phase 1/1b Trial Design on the Company’s SETD2 Inhibitor, EZM0414, at the 2021 ASH Annual Meeting

Epizyme, Inc. to Present New Data from Oncology Portfolio at 2021 American Society of Hematology Annual Meeting

Epizyme: Taking Advantage Of Recent Sell-Off

Third quarter 2021 earnings released: US$0.64 loss per share (vs US$0.55 loss in 3Q 2020)

Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?

Director Kevin Conroy has joined 4th company board

Consensus revenue estimates increase to US$53.4m

Second quarter 2021 earnings released: US$0.63 loss per share (vs US$0.58 loss in 2Q 2020)

Price target decreased to US$11.14

Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts

Epizyme, Inc.(NasdaqGS:EPZM) dropped from Russell 3000E Value Index

Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme gains as peer Constellation attracts sizable premium from MorphoSys

Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.51 loss in 1Q 2020)

Independent Chairman recently bought US$500k worth of stock

Epizyme, Inc. Outlines Clinical Progress, Tazverik Development Strategy and Pipeline Priorities During Company’s Strategic Vision Call

Analysts lower revenue estimates to US$49.1m

Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%

Full year 2020 earnings released: US$2.30 loss per share (vs US$1.93 loss in FY 2019)

Price target lowered to US$21.25

Revenue and earnings beat expectations

Epizyme, Inc. Provides Update on Clinical Trials

New 90-day low: US$10.67

Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?

Epizyme says Boehringer terminates collaboration agreement

Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?

Independent Director recently bought US$60k worth of stock

Price target lowered to US$23.50

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Analysts update estimates

Third quarter 2020 earnings released: US$0.55 loss per share

Revenue and earnings miss expectations

Epizyme, Inc. Announces Executive Promotions

New 90-day low: US$10.34

Epizyme Q3 2020 Earnings Preview

Epizyme Announces Two Lancet Oncology Publications on TAZVERIK Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma

New 90-day low: US$11.52

New 90-day low - US$12.00

New 90-day low - US$12.13

First half earnings released

New 90-day low - US$13.84